Jazz Pharmaceuticals (JAZZ) Short-Term Debt issuances (2011)
Jazz Pharmaceuticals' quarterly Short-Term Debt issuances came in at -$4.0 million in Q3 2011, down 19.4% quarter-over-quarter from -$3.4 million in Q1 2011.
Jazz Pharmaceuticals has reported Short-Term Debt issuances for 1 years, with the latest figure at -$4.0 million in Q3 2011.
- For the quarter ending Q3 2011, Short-Term Debt issuances changed N/A year-over-year to -$4.0 million; the trailing twelve-month figure through Sep 2019 stood at -$4.0 million (changed N/A YoY), and the FY2020 full-year result was $500.0 million, changed N/A from the prior year.
- Short-Term Debt issuances for Q3 2011 stood at -$4.0 million, down from -$3.4 million in the prior quarter.
- The five-year high for Short-Term Debt issuances was -$3.4 million in Q1 2011, with the low at -$4.0 million in Q3 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -33,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2011 | -4.00 Mn |
| Sep 30, 2011 | -4.00 Mn |
| Mar 31, 2011 | -3.35 Mn |
| Mar 31, 2011 | -3.35 Mn |